Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug

FLEMINGTON, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (OTCBB: ARNI) announced today that it has signed an exclusive, worldwide licensing agreement with privately held Invivis Pharmaceuticals to develop the investigational drug, onapristone, an anti-progestin hormone blocker that has been shown to have considerable anti-tumor activity in breast cancer. “Almost half of all breast cancers are associated with a bio-marker which may predict for the activity of onapristone regardless of menopausa

Feed Date: 
Tue, 2012-02-14 12:05